'More May Be Less' in Metastatic Cervical Cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 2
Volume 6
Issue 2

VIENNA--A new study from the EORTC Gynecologic Cancer Cooperative Group (GCCG) has challenged the assumption that aggressive combination chemotherapy is worthwhile in chemotherapy-naïve women with metastatic squamous cell cancer of the cervix.

VIENNA--A new study from the EORTC Gynecologic Cancer Cooperative Group(GCCG) has challenged the assumption that aggressive combination chemotherapyis worthwhile in chemotherapy-naïve women with metastatic squamouscell cancer of the cervix.

Although a highly active four-drug combination yielded a response ratesuperior to that seen with cisplatin alone, it resulted in substantiallygreater hematologic and nonhematologic toxicity, and afforded no survivaladvantage, Dr. Jan Vermorken of Amsterdam's Free University Hospital, saidat the European Society for Medical Oncology Congress.

The study documented a 31% response rate in the 143 women assigned toBEMP (bleomycin, vindesine, mitomycin C, cisplatin) versus 19% in the 144platinum-treated patients.

This benefit was achieved at the cost of more frequent complications,treatment delays, and dose reductions. At 6 years' follow-up, survivalcurves for the two regimens were superimposable.

Related Videos
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Developing novel regimens may continue to improve survival outcomes of patients with advanced cervical cancer following the FDA approval of pembrolizumab and chemoradiation, says Jyoti S. Mayadev, MD.
Treatment with pembrolizumab plus chemoradiation appears to be well tolerated with no detriment to quality of life among those with advanced cervical cancer.
Jyoti S. Mayadev, MD, says that pembrolizumab in combination with chemoradiation will be seamlessly incorporated into her institution’s treatment of those with FIGO 2014 stage III to IVA cervical cancer following the regimen’s FDA approval.
Despite the addition of a TIGIT inhibitor to a checkpoint inhibitor resulting in high levels of safety, there is no future for that combination alone, according to Ritu Salani, MD.
Treatment with tisotumab vedotin may be a standard of care in second- or third-line recurrent or metastatic cervical cancer, says Brian Slomovitz, MD, MS, FACOG.
Domenica Lorusso, MD, PhD, says that paying attention to the quality of chemoradiotherapy is imperative to feeling confident about the potential addition of pembrolizumab for locally advanced cervical cancer.
Guidelines from the Society of Gynecologic Oncology may help with managing the ongoing chemotherapy shortage in the treatment of patients with gynecologic cancers, according to Brian Slomovitz, MD, MS, FACOG.
Related Content